Literature DB >> 26734831

Myalgias and Myopathies: Fibromyalgia.

Jason McCarthy1.   

Abstract

Fibromyalgia is a syndrome of chronic widespread pain typically accompanied by fatigue, nonrestorative sleep, cognitive dysfunction, and mood disorders. As defined by the 2010 American College of Rheumatology criteria, fibromyalgia affects approximately 5% of the population and is the second most common disorder, after osteoarthritis, for which patients are referred to rheumatology subspecialists. These criteria provide a framework for diagnosing fibromyalgia that does not require tender points and incorporates other symptoms of the syndrome in addition to pain. Extensive laboratory tests and imaging are not required to diagnose fibromyalgia. A patient-centered, multimodal approach that includes patient education, behavioral therapy, a graded exercise program, and pharmacotherapy should be used for patients with fibromyalgia. Prescribers must be mindful of adverse drug effects and should tailor therapy to the individual patient. Strong evidence of benefit exists for tricyclic antidepressants, cyclobenzaprine, and serotonin-norepinephrine reuptake inhibitors in fibromyalgia management, whereas nonsteroidal anti-inflammatory drugs and opioids have limited proven benefit. Fibromyalgia can cause significant disability and loss of function. Family physicians are well equipped to direct the multimodal care of patients with fibromyalgia. Written permission from the American Academy of Family Physicians is required for reproduction of this material in whole or in part in any form or medium.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26734831

Source DB:  PubMed          Journal:  FP Essent        ISSN: 2159-3000


  2 in total

1.  Effectiveness and adverse effects of the use of mirtazapine as compared to duloxetine for fibromyalgia: real-life data from a retrospective cohort.

Authors:  Pankti Mehta; Amartya Basu; Sakir Ahmed
Journal:  Rheumatol Int       Date:  2022-04-27       Impact factor: 3.580

Review 2.  Environmental Chemical Assessment in Clinical Practice: Unveiling the Elephant in the Room.

Authors:  Nicole Bijlsma; Marc M Cohen
Journal:  Int J Environ Res Public Health       Date:  2016-02-02       Impact factor: 3.390

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.